Matt Hellmann
我是一名医学肿瘤学家和药物开发人员，热衷于为癌症患者带来改变实践的药物. 担任澳门葡京网赌游戏早期肿瘤发展副总裁, 我负责肿瘤药物早期投资组合的战略规划和执行.
I oversee a growing, 全球团队包括临床项目, 转化医学和癌症生物标志物开发, 并领导澳门葡京网赌游戏多样化的早期肿瘤产品组合, 专注于实体肿瘤肿瘤学.
我在约翰霍普金斯大学医学院完成了医学训练, 马萨诸塞州总医院, 纪念斯隆·凯特琳癌症中心. 我之前是纪念斯隆·凯特琳癌症中心的主治医师, 我专注于治疗肺癌患者, 开发新的免疫疗法, 确定免疫疗法的生物标志物.
那些临床和科学上的成功让我无比兴奋，也让我走上了成为一名药物开发人员的道路. 我很高兴每天在澳门葡京网赌游戏的工作中都能使用这种临床基础.
CURRENT ROLE
2023 – present
2021 – present
2014 – 2021
Featured publications
非小细胞肺癌获得性免疫治疗耐药的临床和分子特征
Memon D, Schoenfeld AJ , Ye D , Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Cancer Cell. 2024 Feb;42(2): 209–224.
Nivolumab联合ipilimumab治疗晚期非小细胞肺癌
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. N Engl J Med. 2019 Nov;381(21):2020-2031.
靶向新一代测序分析非小细胞肺癌患者对抗程序性细胞死亡(PD)-1和抗程序性死亡配体1 (PD- l1)阻断反应的分子决定因素
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. J Clin Oncol. 2018 March;36(7):633-641.
晚期非小细胞肺癌患者联合免疫治疗反应的基因组特征
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin, LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Cancer Cell. 2018 May;33(5), 843–852.e4.
纳武单抗联合伊匹单抗治疗肿瘤突变负担高的肺癌
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. N Engl J Med. 2018 May;378(22):2093-2104.
突变景观决定了非小细胞肺癌对PD-1阻断的敏感性
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Science. 2015年4月,348 (6230):124 - 128.
Veeva ID: Z4-65546
筹备日期:2024年6月